Project Grant R43EY037619
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $330K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Fort Worth, TX 76107, USA
Similar Awards
- This $399,865 federal Project Grant was awarded on September 30, 2025 by the National Eye Institute (NEI), under the CFDA program "Vision Research", to Kuria Therapeutics, Inc. The grant will fund IND-enabling studies of KTX-1161, a novel topical eye drop intended to protect corneal endothelial cells during cataract surgery and treat Fuchs' endothelial corneal dystrophy. The three specific aims are to 1) conduct GLP genotoxicity studies on the active ingredient SCO-116, 2) perform...
- This Project Grant award of $394,285, funded by the National Eye Institute (CFDA 93.867 - Vision Research), supports research at the University of Houston to develop decorin-based drugs for treating corneal scarring and neovascularization. The key objectives are to characterize the binding interfaces of decorin with TGF-β1 and VEGFR2 in order to engineer novel decorin mimetic drugs. This research aims to provide alternative treatment options for preventing corneal opacity and vision loss...
- This $332,179 Project Grant awarded by the National Eye Institute (CFDA 93.867 Vision Research) supports the development of nanobarrier contact lenses that can provide sustained delivery of the drug cysteamine to treat the ocular complications of cystinosis. The lenses are designed to replace the current 8-times daily eye drop regimen, improving patient compliance and reducing side effects from the preservatives and acidic pH in the eye drops. The project aims to demonstrate the lenses can...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $321,904 Project Grant to Proteris Biotech, Inc. through the Vision Research federal grant program (CFDA 93.867). The award, spanning August 1, 2025 to July 31, 2026, will fund the early development of the natural tear protein clusterin (CLU) as a novel approach to treat dry eye disease. The research aims to conduct non-GMP stability analysis of the drug substance and product, as well as perform...
- This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides $450,300 to support research aimed at understanding how corneal limbal stem cells function during wound healing. The project, being conducted by The Regents of the University of California, San Francisco (UCSF), seeks to advance the understanding of limbal stem cell populations and their role in maintaining corneal homeostasis and enabling corneal wound repair. This...
- This Project Grant award of $212,936.00 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research by the University of Louisville to optimize C-MET signaling to enhance corneal epithelial homeostasis. The research aims to determine if inhibiting the ubiquitylation and downregulation of the C-MET receptor can prolong its signaling and accelerate corneal wound healing. This is particularly relevant as corneal blindness is the 4th leading cause of blindness globally, often...
- This Cooperative Agreement award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop a novel fenofibrate-loaded microemulsion (FENO-ME) eyedrop as a non-steroid treatment for nitrogen mustard (NM)-induced corneal injury. The $22,677 award to Virginia Commonwealth University (VCU) spans from Sep 2025 to May 2030. The project seeks to: 1) Validate PPARα signaling as a drug target for NM-induced corneal injury and optimize the FENO-ME eyedrop formulation; 2)...
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $586,258 project grant to Wayne State University to characterize the role of eosinophils in modulating the corneal response to Pseudomonas aeruginosa-induced infection. The 4-year project, commencing on July 1, 2025 and completing on April 30, 2029, aims to investigate the spatiotemporal distribution, phenotypic profiles, and proteomic changes of eosinophils during corneal infection. The...
- This federal Project Grant award of $306,118 was provided by the National Eye Institute (CFDA 93.867 - Vision Research) to Eyescreen, Inc. for the project "DRUG SCREENING PLATFORM IN THE LIGHT-RESPONSIVE HUMAN EYE". The goal of this award is to develop new technology and assays to test the efficacy and safety of investigational new drugs (INDs) for blinding diseases like age-related macular degeneration, diabetic retinopathy, glaucoma, and inherited retinal degenerations using...
- This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides funding of $294,662 to Proteris Biotech, Inc. to support research on using the protein Clusterin (CLU) to treat ocular surface disease and dry eye. The project aims to determine whether CLU can protect the ocular surface epithelia from damage and also have an anti-inflammatory effect in dry eye disease. Recombinant human CLU will be tested for efficacy in a mouse...